UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 8, 2022

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Unity Biotechnology, Inc.

File No. 1-38470 -- CF# 37346

Unity Biotechnology, Inc. submitted an application under Rule 24b-2 requesting extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 6, 2019.

Based on representations by Unity Biotechnology, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.22 through March 6, 2032

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Robert Errett Chief, Disclosure Management Office